Get the Stockscreener App
2.85
0.35%
-0.010
Orchestra Biomed Holdings Inc stock is traded at $2.85, with a volume of 41,087.
It is down -0.35% in the last 24 hours and down -30.74% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$2.86
Open:
$2.86
24h Volume:
41,087
Relative Volume:
0.73
Market Cap:
$107.28M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-1.90
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
+9.62%
1M Performance:
-30.74%
6M Performance:
-47.42%
1Y Performance:
-38.31%
1-Day Range:
$2.77
$2.949
1-Week Range:
$2.57
$3.26
52-Week Range:
$2.49
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.85 | 107.28M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy - MSN
Orchestra BioMed’s Strategic Advances in Medical Innovations - TipRanks
What is B. Riley’s Estimate for OBIO Q1 Earnings? - Defense World
Chardan Capital Has Strong Outlook for OBIO FY2025 Earnings - Defense World
Orchestra BioMed (NASDAQ:OBIO) Upgraded at B. Riley - Defense World
HC Wainwright Has Lowered Expectations for Orchestra BioMed (NASDAQ:OBIO) Stock Price - Defense World
H.C. Wainwright cuts Orchestra BioMed stock target to $12 By Investing.com - Investing.com Australia
Where Orchestra BioMed Hldgs Stands With Analysts - Benzinga
Health Check: How Prudently Does Orchestra BioMed Holdings (NASDAQ:OBIO) Use Debt? - simplywall.st
HighTower Advisors LLC Has $274,000 Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra BioMed (NASDAQ:OBIO) Earns Buy Rating from Chardan Capital - Defense World
BTIG maintains $12 target on Orchestra BioMed stock - Investing.com Australia
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates - MSN
Orchestra BioMed (NASDAQ:OBIO) Posts Earnings Results, Hits Estimates - MarketBeat
BTIG maintains $12 target on Orchestra BioMed stock By Investing.com - Investing.com Canada
OBIO stock touches 52-week low at $3.63 amid market challenges By Investing.com - Investing.com South Africa
OBIO stock touches 52-week low at $3.63 amid market challenges - Investing.com Australia
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update - The Manila Times
Orchestra BioMed Secures $30M Funding While Advancing Key Clinical Trials Despite Wider Losses - Stock Titan
(OBIO) Trading Advice - news.stocktradersdaily.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Freightos And 2 Other Penny Stocks Worth Watching - simplywall.st
Orchestra BioMed (NASDAQ:OBIO) Research Coverage Started at BTIG Research - ETF Daily News
Orchestra BioMed (NASDAQ:OBIO) Coverage Initiated at BTIG Research - The AM Reporter
BTIG Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy Recommendation - Nasdaq
BTIG sets Orchestra BioMed stock with $12 target By Investing.com - Investing.com Australia
Insiders In Orchestra BioMed Holdings Left Out From 10% Price Rise After Disposing Stock - simplywall.st
BTIG Initiates Orchestra BioMed at Buy With $12 Price Target -March 20, 2025 at 07:15 am EDT - Marketscreener.com
Orchestra BioMed (OBIO) Projected to Post Earnings on Wednesday - Defense World
Orchestra BioMed (NASDAQ:OBIO) Given Buy Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $14 target on Orchestra BioMed stock By Investing.com - Investing.com South Africa
Promising Clinical Developments and Strategic Advancements Drive Buy Rating for Orchestra BioMed Holdings - TipRanks
Dr. Vivek Reddy Joins Orchestra BioMed to Lead Breakthrough Hypertension Study - MSN
Orchestra BioMed Highlights Strategic Initiatives and Innovations - TipRanks
Orchestra BioMed to Participate in Upcoming Investor Conferences - MSN
Orchestra BioMed Updates Executive Compensation Policies - TipRanks
Orchestra BioMed Welcomes Christopher Cleary to Board of Directors - MSN
Orchestra BioMed to Present at Upcoming Investor Conferences - GlobeNewswire
3 Major Healthcare Conferences Where Orchestra BioMed Will Share Its Growth Story - StockTitan
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive - GlobeNewswire
Mount Sinai's Top Cardiac Expert Takes Helm of Groundbreaking Hypertension Treatment Study - StockTitan
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):